GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer

被引：0
|
作者：
Olislagers, M. [1 ]
De Jong, F. C. [1 ]
Van Etten, V. M. J. [1 ]
Kan, T. W. [1 ]
Zuiverloon, T. C. M. [1 ]
机构：
[1] Erasmus MC, Dept Urol, Rotterdam, Netherlands
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0281
引用
收藏
页码：S405 / S406
页数：2
相关论文
共 50 条
  • [31] BCG plus Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned
    Hayne, Dickon
    Stockler, Martin
    McCombie, Steve P.
    Lawrence, Nicola
    Martin, Andrew
    Sengupta, Shomik
    Davis, Ian D.
    BJU INTERNATIONAL, 2017, 119 : 55 - 57
  • [32] Long-term outcomes among BCG-treated high-risk non-muscle invasive bladder cancer patients in an equal access setting.
    Williams, Stephen B.
    Howard, Lauren
    Foster, Meagan
    Klaassen, Zachary William Abraham
    Sieluk, Jan
    Li, Haojie
    Imai, Kentaro
    Sbar, Eric
    De Hoedt, Amanda M.
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Combination Therapy for High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) with and without BCG Pretreatment
    Rexer, Heidrun
    Grimm, Marc-Oliver
    Ohlmann, Carsten-H.
    AKTUELLE UROLOGIE, 2024, 55 (05) : 412 - 413
  • [34] Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy
    Yates, D. R.
    Roupret, M.
    WORLD JOURNAL OF UROLOGY, 2011, 29 (04) : 415 - 422
  • [35] Bladder Epicheck® for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience
    Velasco, J. Cano
    Pujol, L. Polanco
    Cortes, J. C. Moreno
    Puentedura, A. Lafuente
    Fernandez, C. Hernandez
    ACTAS UROLOGICAS ESPANOLAS, 2023, 47 (08): : 471 - 473
  • [36] Long-Term Outcomes and Costs Among BCG-treated High-Risk Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting
    Williams, S. B.
    Howard, L. E.
    Foster, M. L.
    Klaassen, Z.
    Li, H.
    Sieluk, J.
    Imai, K.
    Sbar, E., I
    De Hoedt, A. M.
    Freedland, S. J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (12) : 902 - 902
  • [37] Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non-Muscle-Invasive Bladder Cancer
    van Rhijn, Bas W. G.
    Zuiverloon, Tahlita C. M.
    Vis, Andre N.
    Radvanyi, Francois
    van Leenders, Geert J. L. H.
    Ooms, Bert C. M.
    Kirkels, Wim J.
    Lockwood, Gina A.
    Boeve, Egbert R.
    Jobsis, Adriaan C.
    Zwarthoff, Ellen C.
    van der Kwast, Theo H.
    EUROPEAN UROLOGY, 2010, 58 (03) : 433 - 441
  • [38] Effect of Re-TUR time on recurrence and progression in high-risk non-muscle-invasive bladder cancer
    Demir, Demirhan O.
    Doluoglu, Omer G.
    Yildiz, Ali K.
    Kacan, Turgay
    Yazar, Veli M.
    Demirbas, Arif
    Ozgur, Berat C.
    CIRUGIA Y CIRUJANOS, 2022, 90 : 6 - 12
  • [39] Her2 Amplification Is Associated with a High Risk of Progression in Non-Muscle-Invasive Bladder Cancer
    Pan, C-C
    LABORATORY INVESTIGATION, 2012, 92 : 232A - 232A
  • [40] SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
    Lindgren, Maria Skydt
    Lamy, Philippe
    Lindskrog, Sia Viborg
    Christensen, Emil
    Nordentoft, Iver
    Birkenkamp-Demtroder, Karin
    Ulhoi, Benedicte Parm
    Jensen, Jorgen Bjerggaard
    Dyrskjot, Lars
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 34 : 59 - 67
12345